Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock ...

Tempus AI Inc (NASDAQ:TEM) shares closed up 14.5% following the announcement of expanded strategic partnerships with ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with ...

Chuck Davis, Mark Zuckerberg, Jamie Dimon, and Max de Groen were among other top executives who sold their stake in their ...

Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

Many of America’s wealthiest business leaders have lost millions — if not billions — of dollars in net worth since the start of the year, as President Donald Trump’s policies hit markets. But some ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Meta Platforms Chief Executive Officer (CEO) Mark Zuckerberg and JPMorgan Chase & Co. CEO Jamie Dimon were among eight other top executives who sold their shares before US President Donald Trump ...